IceCure signs exclusive ProSense distribution deal with Scovas Medical in Netherlands

Reuters2026/08/24 12:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IceCure Medical entered an exclusive distribution agreement with Scovas Medical for ProSense cryoablation systems in the Netherlands.
Deal covers breast cancer treatment and interventional oncology, supporting broader commercialization in a key European market.
Initial term includes an option to negotiate a longer-term agreement, subject to mutual consent.
Partnership aligns with the Netherlands-based THERMAC trial, now in Phase III with cryoablation selected for continued evaluation.
Prior THERMAC data cited a 94% complete ablation rate, 0% complication rate, 100% treatment tolerance without general anesthesia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-092807), on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IceCure signs exclusive ProSense distribution deal with Scovas Medical in Netherlands

You may also like

Crypto prices